Authors: Martha Powell, Future Science Group
The Global Antibiotic Research and Development Partnership (GARDP; Geneva, Switzerland) has joined forces with Novartis (Basel, Switzerland) to accelerate the development and availability of generic antibiotic treatments for children in low- and middle-income countries.
Currently, infectious diseases, including serious bacterial infections such as pneumonia and sepsis, are leading causes of child morbidity and mortality. However, treatment options for this vulnerable population are limited and rising drug resistance poses a serious concern.
Restricted Content / Members Only
